X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3319) 3319
Book Review (828) 828
Publication (159) 159
Newsletter (25) 25
Magazine Article (18) 18
Book Chapter (17) 17
Book / eBook (4) 4
Conference Proceeding (4) 4
Web Resource (3) 3
Dissertation (1) 1
Government Document (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (2986) 2986
humans (2924) 2924
female (2825) 2825
medroxyprogesterone acetate (1271) 1271
middle aged (1088) 1088
adult (1067) 1067
obstetrics & gynecology (1013) 1013
medroxyprogesterone acetate - adverse effects (826) 826
medroxyprogesterone acetate - administration & dosage (673) 673
abridged index medicus (574) 574
women (567) 567
aged (562) 562
contraceptive agents, female - adverse effects (513) 513
postmenopausal women (508) 508
medroxyprogesterone - adverse effects (507) 507
hormone replacement therapy (496) 496
pregnancy (443) 443
risk factors (433) 433
adolescent (426) 426
menopause (423) 423
medroxyprogesterone (399) 399
estrogen replacement therapy - adverse effects (398) 398
estrogen (391) 391
male (382) 382
animals (373) 373
contraceptive agents, female - administration & dosage (353) 353
medroxyprogesterone acetate - therapeutic use (339) 339
risk (338) 338
medroxyprogesterone - administration & dosage (334) 334
postmenopause (327) 327
contraception (319) 319
medroxyprogesterone - analogs & derivatives (292) 292
prospective studies (285) 285
medicine, general & internal (278) 278
medroxyprogesterone - therapeutic use (269) 269
delayed-action preparations (267) 267
estrogen replacement therapy (266) 266
time factors (264) 264
progesterone (262) 262
depot medroxyprogesterone acetate (259) 259
endocrinology & metabolism (258) 258
hormone therapy (256) 256
health aspects (253) 253
treatment outcome (253) 253
double-blind method (246) 246
population (241) 241
oncology (238) 238
estrogens, conjugated - adverse effects (237) 237
obstetrics and gynecology (237) 237
estrogens, conjugated - administration & dosage (217) 217
medroxyprogesterone acetate - pharmacology (215) 215
estradiol - administration & dosage (214) 214
bone density - drug effects (211) 211
drug therapy, combination (211) 211
oral-contraceptives (193) 193
cancer (192) 192
estradiol (189) 189
injections, intramuscular (180) 180
randomized controlled-trial (175) 175
young adult (175) 175
estrogens, conjugated - therapeutic use (174) 174
breast cancer (172) 172
drug administration schedule (171) 171
randomized controlled trials as topic (171) 171
dose-response relationship, drug (170) 170
progestins - adverse effects (170) 170
administration, oral (164) 164
breast neoplasms - drug therapy (164) 164
replacement therapy (163) 163
pharmacology & pharmacy (162) 162
reproductive biology (160) 160
depot-medroxyprogesterone acetate (159) 159
follow-up studies (158) 158
conjugated equine estrogens (157) 157
drug combinations (154) 154
bone-mineral density (152) 152
research (150) 150
care and treatment (149) 149
double-blind (144) 144
osteoporosis (143) 143
breast-cancer (138) 138
breast neoplasms - chemically induced (137) 137
norethindrone - analogs & derivatives (137) 137
hormones (135) 135
birth control (134) 134
therapy (134) 134
analysis (133) 133
clinical trials as topic (133) 133
progestin (133) 133
womens health (133) 133
medicine & public health (131) 131
oral contraceptives (131) 131
medroxyprogesterone - pharmacology (130) 130
estrogen plus progestin (129) 129
estrogens - adverse effects (129) 129
progestins - administration & dosage (129) 129
estrogen replacement therapy - methods (125) 125
women's health (124) 124
contraceptives (123) 123
estradiol - adverse effects (123) 123
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3200) 3200
Japanese (38) 38
German (35) 35
French (31) 31
Spanish (23) 23
Italian (9) 9
Chinese (8) 8
Czech (7) 7
Swedish (7) 7
Dutch (5) 5
Russian (4) 4
Danish (3) 3
Polish (3) 3
Portuguese (2) 2
Afrikaans (1) 1
Croatian (1) 1
Hebrew (1) 1
Hungarian (1) 1
Norwegian (1) 1
Serbian (1) 1
Slovak (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Gynecological Endocrinology, ISSN 0951-3590, 10/2012, Volume 28, Issue S2, pp. 12 - 15
Gene expression analysis of healthy postmenopausal women in a prospective clinical study indicated that genes encoding for epithelial proliferation markers... 
bcl-2 protein | percutaneous estradiol | proliferation | normal breast tissue | micronized progesterone | gene expression | Bcl-2 protein | Normal breast tissue | Micronized progesterone | Proliferation | Gene expression | HT | Percutaneous estradiol | IGF-I | CANCER CELLS | MEDROXYPROGESTERONE ACETATE | RISK | CELL-PROLIFERATION | HORMONE REPLACEMENT THERAPY | OBSTETRICS & GYNECOLOGY | ENDOCRINOLOGY & METABOLISM | ESTROGEN PLUS PROGESTIN | POSTMENOPAUSAL WOMEN | EXPRESSION | GROWTH-FACTOR-I | Humans | Middle Aged | Ki-67 Antigen - metabolism | Gene Expression Profiling | Administration, Cutaneous | Mammary Glands, Human - metabolism | RNA, Messenger - metabolism | Mammary Glands, Human - abnormalities | Estradiol - adverse effects | Medroxyprogesterone Acetate - adverse effects | Postmenopause | Adult | Female | Breast Neoplasms - epidemiology | Mammary Glands, Human - drug effects | Mammary Glands, Human - cytology | Estradiol - therapeutic use | Gels | Administration, Oral | Estrogens, Conjugated (USP) - administration & dosage | Risk Factors | Estradiol - administration & dosage | Medroxyprogesterone Acetate - therapeutic use | Sweden - epidemiology | Estrogen Replacement Therapy - adverse effects | Breast Neoplasms - prevention & control | Gene Expression Regulation - drug effects | Estrogens, Conjugated (USP) - therapeutic use | Ki-67 Antigen - genetics | Breast Density | Cell Proliferation - drug effects | Medroxyprogesterone Acetate - administration & dosage | Estrogens, Conjugated (USP) - adverse effects | Index Medicus
Journal Article
JAMA - Journal of the American Medical Association, ISSN 0098-7484, 2013, Volume 310, Issue 13, pp. 1353 - 1368
IMPORTANCE Menopausal hormone therapy continues in clinical use but questions remain regarding its risks and benefits for chronic disease prevention. OBJECTIVE... 
BREAST-CANCER | INSOMNIA RATING-SCALE | MEDICINE, GENERAL & INTERNAL | REPLACEMENT THERAPY | PLACEBO-CONTROLLED TRIAL | QUALITY-OF-LIFE | ESTROGEN PLUS PROGESTIN | CORONARY-HEART-DISEASE | MILD COGNITIVE IMPAIRMENT | POSTMENOPAUSAL WOMEN | CONJUGATED EQUINE ESTROGEN | United States - epidemiology | Follow-Up Studies | Humans | Middle Aged | Coronary Disease - epidemiology | Risk | Hormone Replacement Therapy - adverse effects | Pulmonary Embolism - epidemiology | Estrogens - adverse effects | Medroxyprogesterone Acetate - adverse effects | Postmenopause | Female | Stroke - epidemiology | Drug Therapy, Combination | Breast Neoplasms - epidemiology | Colorectal Neoplasms - epidemiology | Estrogens, Conjugated (USP) - administration & dosage | Treatment Outcome | Endometrial Neoplasms - epidemiology | Hip Fractures - epidemiology | Breast Neoplasms - prevention & control | Coronary Disease - prevention & control | Quality of Life | Aged | Medroxyprogesterone Acetate - administration & dosage | Estrogens, Conjugated (USP) - adverse effects | Estrogens - administration & dosage | Women | Care and treatment | Research | Hormone therapy | Health aspects | Menopause | Womens health | Estrogen | Endocrine therapy | Clinical trials | Cardiovascular disease | Breast cancer | Progesterone | Index Medicus | Abridged Index Medicus
Journal Article
The Journal of Clinical Endocrinology & Metabolism, ISSN 0021-972X, 02/2014, Volume 99, Issue 2, pp. E189 - E198
Journal Article
Journal of Thrombosis and Haemostasis, ISSN 1538-7933, 01/2013, Volume 11, Issue 1, pp. 124 - 131
Roach REJ, Lijfering WM, Helmerhorst FM, Cannegieter SC, Rosendaal FR, van Hylckama Vlieg A. The risk of venous thrombosis in women over 50 years old using... 
epidemiology | oral contraception | venous thrombosis | postmenopausal hormone therapy | THROMBOEMBOLIC DISEASE | ROUTE | METAANALYSIS | PROTHROMBOTIC MUTATIONS | MEDROXYPROGESTERONE ACETATE | DEEP-VEIN THROMBOSIS | IMPACT | FACTOR-V-LEIDEN | REPLACEMENT THERAPY | ESTROGEN | PERIPHERAL VASCULAR DISEASE | HEMATOLOGY | Venous Thrombosis - diagnosis | Venous Thrombosis - chemically induced | Age Factors | Desogestrel - adverse effects | Humans | Middle Aged | Netherlands - epidemiology | Progestins - adverse effects | Administration, Cutaneous | Estrogens - adverse effects | Case-Control Studies | Norethindrone - analogs & derivatives | Norethindrone - adverse effects | Estradiol - adverse effects | Medroxyprogesterone Acetate - adverse effects | Postmenopause | Female | Odds Ratio | Transdermal Patch | Contraceptives, Oral, Hormonal - adverse effects | Risk Assessment | Risk Factors | Logistic Models | Estrogen Replacement Therapy - adverse effects | Levonorgestrel - adverse effects | Progestins - administration & dosage | Venous Thrombosis - epidemiology | Sex Factors | Aged | Estrogens, Conjugated (USP) - adverse effects | Estrogens - administration & dosage | Usage | Progestational hormones, Synthetic | Contraceptive drugs | Hormone therapy | Thrombin | Thrombophlebitis | Postmenopausal women | Contraception | Estradiol | Risk factors | Index Medicus
Journal Article
Nature, ISSN 0028-0836, 11/2010, Volume 468, Issue 7320, pp. 103 - 107
RANK ligand (RANKL), a TNF-related molecule, is essential for osteoclast formation, function and survival through interaction with its receptor RANK. Mammary... 
CELL FUNCTION | OSTEOPROTEGERIN-LIGAND | MULTIDISCIPLINARY SCIENCES | MEDROXYPROGESTERONE ACETATE | RECEPTOR | HORMONE REPLACEMENT THERAPY | HUMAN BREAST-TUMORS | OSTEOCLAST DIFFERENTIATION | EXPRESSION | GLAND DEVELOPMENT | TRANSGENIC MICE | Epithelial Cells - metabolism | RANK Ligand - metabolism | Progesterone - administration & dosage | Epithelial Cells - drug effects | Humans | Progestins - adverse effects | Cell Transformation, Neoplastic - chemically induced | Mammary Neoplasms, Experimental - metabolism | Mammary Neoplasms, Experimental - genetics | Breast Neoplasms - metabolism | Lung Neoplasms - secondary | Mammary Neoplasms, Experimental - pathology | Medroxyprogesterone Acetate - adverse effects | Female | Precancerous Conditions - pathology | Receptor Activator of Nuclear Factor-kappa B - metabolism | Disease Models, Animal | 9,10-Dimethyl-1,2-benzanthracene - administration & dosage | Neoplasm Invasiveness | Mice, Inbred C57BL | Epithelial Cells - pathology | Mice, Transgenic | Progesterone - adverse effects | Mammary Neoplasms, Experimental - chemically induced | RANK Ligand - genetics | Animals | RANK Ligand - antagonists & inhibitors | Breast Neoplasms - pathology | Progestins - administration & dosage | Receptor Activator of Nuclear Factor-kappa B - genetics | Cell Proliferation - drug effects | Medroxyprogesterone Acetate - administration & dosage | Mice | Cell Transformation, Neoplastic - drug effects | Precancerous Conditions - prevention & control | Cell Transformation, Neoplastic - pathology | Mammary Tumor Virus, Mouse - genetics | Mammary Tumor Virus, Mouse - physiology | 9,10-Dimethyl-1,2-benzanthracene - adverse effects | Immunohistochemistry | Care and treatment | Usage | Physiological aspects | Breast cancer | Genetic aspects | Research | Progesterone | Tumor proteins | Health aspects | Risk factors | Proteins | Hormone replacement therapy | Rodents | Apoptosis | Index Medicus
Journal Article
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, ISSN 0098-7484, 09/2017, Volume 318, Issue 10, pp. 927 - 938
Journal Article
Journal Article
Journal Article
Fertility and Sterility, ISSN 0015-0282, 2009, Volume 92, Issue 3, pp. 1025 - 1038
Objective To evaluate the effects of a tissue-selective estrogen complex (TSEC) composed of bazedoxifene/conjugated estrogens (BZA/CE) on menopausal symptoms,... 
Internal Medicine | Obstetrics and Gynecology | breast pain | Bazedoxifene | hot flushes | metabolism | vaginal atrophy | conjugated estrogens | coagulation | PLACEBO | RISK-FACTORS | MEDROXYPROGESTERONE ACETATE | OSTEOPOROSIS | OBSTETRICS & GYNECOLOGY | TRIAL | REPRODUCTIVE BIOLOGY | DISEASE | POSTMENOPAUSAL WOMEN | RECEPTOR MODULATOR | LIPIDS | Carbohydrate Metabolism - drug effects | Estrogens, Conjugated (USP) - pharmacology | Estrogens - pharmacology | Vagina - drug effects | Humans | Middle Aged | Atrophy - pathology | Selective Estrogen Receptor Modulators - adverse effects | Homocysteine - metabolism | Estrogens - adverse effects | Estrogens - therapeutic use | Dose-Response Relationship, Drug | Menopause - drug effects | Selective Estrogen Receptor Modulators - therapeutic use | Adult | Female | Indoles - pharmacology | Atrophy - drug therapy | Drug Therapy, Combination | Vagina - pathology | Hot Flashes - drug therapy | Double-Blind Method | Treatment Outcome | Estrogens, Conjugated (USP) - therapeutic use | Indoles - adverse effects | Menopause - metabolism | Outpatients | Lipid Metabolism - drug effects | Indoles - therapeutic use | Aged | Estrogens, Conjugated (USP) - adverse effects | Selective Estrogen Receptor Modulators - pharmacology | Benzoic acid | Women | Medical colleges | Care and treatment | Safety and security measures | Analysis | Menopause | Estrogen | Health aspects | Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 08/2003, Volume 349, Issue 6, pp. 523 - 534
Journal Article
American Journal of Epidemiology, ISSN 0002-9262, 7/2009, Volume 170, Issue 1, pp. 12 - 23
The authors further analyzed results from the Women's Health Initiative randomized trials (1993-2004) of conjugated equine estrogens, with or without... 
Estrogen replacement therapy | Estrogens | Cohort studies | Progestins | Postmenopause | Clinical trial | Hormone replacement therapy | Medroxyprogesterone 17-acetate | clinical trial | progestins | CONJUGATED EQUINE ESTROGENS | CLINICAL-TRIAL | estrogens | VENOUS THROMBOSIS | RANDOMIZED CONTROLLED-TRIAL | BREAST-CANCER | WOMEN | PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH | estrogen replacement therapy | COLORECTAL-CANCER | cohort studies | hormone replacement therapy | CARDIOVASCULAR-DISEASE | postmenopause | ESTROGEN PLUS PROGESTIN | CORONARY-HEART-DISEASE | medroxyprogesterone 17-acetate | Contraceptive Agents, Female - adverse effects | Postmenopause - drug effects | Follow-Up Studies | Contraceptive Agents, Female - therapeutic use | Progestins - therapeutic use | Humans | Menopause | Middle Aged | Progestins - adverse effects | Fractures, Bone - epidemiology | Coronary Disease - epidemiology | Pulmonary Embolism - epidemiology | Estrogens - adverse effects | Estrogens - therapeutic use | Incidence | Washington - epidemiology | Time Factors | Medroxyprogesterone Acetate - adverse effects | Female | Stroke - epidemiology | Retrospective Studies | Breast Neoplasms - epidemiology | Colorectal Neoplasms - epidemiology | Survival Rate - trends | Estrogens, Conjugated (USP) - administration & dosage | Risk Factors | Medroxyprogesterone Acetate - therapeutic use | Thrombosis - epidemiology | Endometrial Neoplasms - epidemiology | Estrogen Replacement Therapy - adverse effects | Breast Neoplasms - prevention & control | Estrogens, Conjugated (USP) - therapeutic use | Coronary Disease - prevention & control | Aged | Estrogens, Conjugated (USP) - adverse effects | Fractures, Bone - prevention & control | Hormone therapy | Conjugated estrogens | Causes of | Postmenopausal women | Breast cancer | Drug therapy | Thromboembolism | Health aspects | Risk factors | Clinical trials | Womens health | Epidemiology | Clinical outcomes | Index Medicus | Original Contributions
Journal Article